RFC
CTMX icon

Russell Frank Company’s CytomX Therapeutics CTMX Stock Holding History

Russell Frank Company’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$419K Buy
32,451
+4,041
+14% +$56.1K ﹤0.01% 2512
2015
Q4 		$591K Buy
+28,410
New +$450K ﹤0.01% 2436

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPI
Canaan Partners IX Menlo Park, California $87.5M AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Russell Frank Company's CTMX Position: Q1 2016 in Review

Russell Frank Company increased its CytomX Therapeutics (CTMX) stake by 14% in Q1 2016, buying an estimated $56.1K and bringing the position to 32,451 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #2512.

Russell Frank Company first reported a position in CTMX in Q4 2015 and has held it in 2 quarters since. The position peaked at $591K in Q4 2015. 49 funds tracked by Wall St. Rank hold CTMX as of Q1 2016.

  • Russell Frank Company held 32,451 shares of CytomX Therapeutics worth $419K as of Q1 2016.
  • Russell Frank Company bought 4,041 CytomX Therapeutics shares in Q1 2016, an estimated $56.1K.
  • CytomX Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2512 holding.
  • Russell Frank Company first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • Russell Frank Company's CytomX Therapeutics position peaked at $591K in Q4 2015.
  • 49 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.